Campbell & CO Investment Adviser LLC Takes Position in Insulet Corporation $PODD

Campbell & CO Investment Adviser LLC acquired a new position in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,441 shares of the medical instruments supplier’s stock, valued at approximately $1,081,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. American Century Companies Inc. boosted its position in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after purchasing an additional 297,734 shares during the period. Nuveen LLC purchased a new stake in shares of Insulet during the 1st quarter valued at approximately $74,163,000. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in Insulet by 1,316.5% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after buying an additional 179,850 shares during the period. Vanguard Group Inc. grew its stake in Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after buying an additional 178,976 shares in the last quarter. Finally, AustralianSuper Pty Ltd grew its stake in Insulet by 487.5% in the 2nd quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock valued at $64,460,000 after buying an additional 170,247 shares in the last quarter.

Insider Activity at Insulet

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on PODD. Jefferies Financial Group increased their price objective on Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Truist Financial raised their price objective on shares of Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Wells Fargo & Company boosted their target price on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, BTIG Research restated a “buy” rating and issued a $370.00 target price on shares of Insulet in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average price target of $374.10.

Insulet Trading Up 3.2%

Shares of PODD stock opened at $336.84 on Thursday. The business has a 50-day moving average price of $324.17 and a two-hundred day moving average price of $311.37. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $23.70 billion, a P/E ratio of 102.38, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s revenue was up 29.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.